Related Experiment Videos
Respiratory immunotoxicity: an in vitro assessment
Erwin L Roggen1, Nanna Kristensen Soni, Geert R Verheyen
1Department of Protein Screening, Molecular Biotechnology, Novozymes AS Smoermosevej 11, 2880 Bagsvaerd, Denmark. elro@novozymes.com
Summary
Developing in vitro tests for respiratory immunotoxicity is challenging. Researchers are exploring epithelial cells (ECs), dendritic cells (DCs), and alveolar macrophages (AMs) in 3D models to assess respiratory agent potency.
Area of Science:
- * Toxicology and Immunology
- * In vitro modeling of respiratory immune responses
Background:
- * Current in vitro methods cannot reliably assess the immunotoxic potential of respiratory agents due to endpoint complexity and limited agent availability.
- * Epithelial cells (ECs) show promise for developing new immunotoxicity tests, with human alveolar cells (A549 cell line) being a convenient model.
- * Existing dendritic cell (DC) and alveolar macrophage (AM) assays have limitations in standardizing protocols and discerning sensitizer potency.
Purpose of the Study:
- * To review the current state and challenges of in vitro assessment for respiratory immunotoxicity.
- * To explore the potential of various cell types (ECs, DCs, AMs) and model systems (3D models) for developing more accurate immunotoxicity tests.
- * To highlight the need for integrated cell models and biomarkers for improved respiratory immunotoxicity evaluation.
Main Methods:
- * Review of existing literature on in vitro immunotoxicity testing for respiratory agents.
- * Assessment of different cell types: airway epithelial cells (A549), dendritic cells (DCs), and alveolar macrophages (AMs).
- * Evaluation of 3D reconstituted human tissue models, including lung models, for assessing compound membrane permeability and immunotoxicity.
Main Results:
- * 3D models using the A549 lung cell line show promising results for in vitro immunotoxicity testing.
- * Current DC-based tests struggle to differentiate sensitizer potency due to protocol and endpoint limitations.
- * Combined cell models (ECs, DCs, AMs) are suggested for ranking sensitizing potency, and 3D tissue models are needed to assess compound membrane crossing.
Conclusions:
- * Integrated in vitro test systems combining multiple cell types (ECs, DCs, AMs) are necessary for accurate respiratory immunotoxicity assessment.
- * 3D reconstituted human lung tissue models require further evaluation for respiratory immunotoxicity testing.
- * The development of early-stage biomarkers predictive of downstream immunotoxicity mechanisms is crucial for the success of simplified in vitro tests.